NCT01644799 Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma Status COMPLETED Phase PHASE1
NCT01629082 Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia Status COMPLETED Phase PHASE1
NCT01617213 Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma Status TERMINATED Phase PHASE2
NCT01615042 Phase I Study of Lenalidomide in Patients With Acute Leukemia Status TERMINATED Phase PHASE1
NCT01615029 Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT01604031 Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide Status TERMINATED Phase PHASE1
NCT01600053 Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia Status TERMINATED Phase PHASE2
NCT01593410 Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE2
NCT01583283 Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma Status COMPLETED Phase PHASE1
NCT01578954 Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction Status COMPLETED Phase PHASE1
NCT01564537 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Status COMPLETED Phase PHASE3
NCT01562405 Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT01559935 Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT01556776 A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Status COMPLETED Phase PHASE3
NCT01556035 Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma Status COMPLETED Phase PHASE2
NCT01555281 Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma Status TERMINATED Phase PHASE1/PHASE2
NCT01553786 Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Status COMPLETED Phase PHASE2
NCT01553149 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Status COMPLETED Phase PHASE2